BioSpace News Archive

Sage Therapeutics, Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced that the Company will participate in a fireside chat at SVB Leerink’s 3rd Annual CNS Forum on June 29th at 4:15pm ET.

AstraZeneca and Merck, known as MSD outside the United States and Canada, announced that LYNPARZA has been granted conditional approval in China as monotherapy for the treatment of adult patients with germline or somatic BRCA-mutated metastatic castration-resistant prostate cancer who have progressed following prior treatment that included a new hormonal agent.

Allergy Therapeutics plc, the fully integrated commercial biotechnology company specialising in allergy immunotherapy, announces a pre-close trading update for the year ended 30 June 2021.

Encouraging Pharmacokinetics, Pharmacodynamics and Safety Profile at 15mg/kg of AVB-500

Yesterday, June 23, stem cell biotechnology company Asymmetrex presented its latest advances in stem cell technology to attendees in the 2021 Annual Meeting of the International Society for Stem Cell Research, which runs from June 21-26.

Anavo Therapeutics announced three key appointments to its Scientific Advisory Board in the persons of Karl-Heinz Altmann, Andrew Mortlock and Gregg Siegal.

About ViaDerma, Inc. ViaDerma, Inc. is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas.

Fennec Pharmaceuticals Inc. announced an amendment to its existing senior debt facility with the Life Sciences Group at Bridge Bank increasing the size of the facility from $18 million to $20 million.

Advanced Aesthetic Technologies, Inc. is proud to announce the initiation of a clinical trial for their Algeness® VL Filler in China in partnership with Lanzhou Biotechnique Development Co., LTD and their parent company China National Biotec Group Co., LTD This study aims to evaluate the effectiveness and safety of Algeness® VL in the treatment of moderate to severe nasolabial folds with commercially available hyaluronic acid fillers for injection as a control.

The U.S. Food and Drug Administration granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company’s investigational antibody therapy for Alzheimer’s disease.